Andrew Biankin
#88,673
Most Influential Person Now
Australian clinician-scientist
Andrew Biankin's AcademicInfluence.com Rankings
Andrew Biankinphilosophy Degrees
Philosophy
#10312
World Rank
#14123
Historical Rank
Logic
#7214
World Rank
#8902
Historical Rank
Andrew Biankinbiology Degrees
Biology
#14101
World Rank
#17764
Historical Rank
Genetics
#1594
World Rank
#1700
Historical Rank
Download Badge
Philosophy Biology
Andrew Biankin's Degrees
- Bachelors Medicine University of Melbourne
Why Is Andrew Biankin Influential?
(Suggest an Edit or Addition)According to Wikipedia, Andrew Victor Biankin is a Scotland-based Australian clinician-scientist, best known for his work on enabling precision oncology in learning healthcare systems by integrating discovery, preclinical and clinical development to accelerate novel therapeutic strategies, and developing standardised pan-cancer assays for use by healthcare systems and researchers worldwide.
Andrew Biankin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Signatures of mutational processes in human cancer (2013) (7589)
- Genomic analyses identify molecular subtypes of pancreatic cancer (2016) (2343)
- Whole genomes redefine the mutational landscape of pancreatic cancer (2015) (1983)
- International network of cancer genome projects (2010) (1839)
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) (1752)
- Patient-derived xenograft models: an emerging platform for translational cancer research. (2014) (1214)
- Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. (2017) (1092)
- An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms (2004) (1007)
- Pancreatic cancer (1988) (797)
- Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes (2007) (781)
- Whole-genome landscape of pancreatic neuroendocrine tumours (2017) (616)
- CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma (2016) (555)
- A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas (2015) (529)
- Interrogating open issues in cancer precision medicine with patient-derived xenografts (2017) (462)
- Molecular subtypes of pancreatic cancer (2019) (415)
- Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling (2014) (399)
- Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. (2006) (385)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Adult cardiac-resident MSC-like stem cells with a proepicardial origin. (2011) (371)
- PINA v2.0: mining interactome modules (2011) (321)
- Role of pancreatic stellate cells in pancreatic cancer metastasis. (2010) (305)
- The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma (2012) (287)
- Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. (2005) (241)
- Margin clearance and outcome in resected pancreatic cancer. (2009) (238)
- Molecular pathways in colorectal cancer (2012) (236)
- Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer (2018) (226)
- Patient-centric trials for therapeutic development in precision oncology (2015) (223)
- Common Activation of Canonical Wnt Signaling in Pancreatic Adenocarcinoma (2007) (223)
- Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas (2004) (223)
- An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. (2005) (213)
- Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy (2015) (199)
- Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis (2017) (198)
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial (2015) (198)
- Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis (2019) (197)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. (2010) (191)
- Aberrant p16INK4A and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma (2002) (180)
- Genome‐wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT‐ROBO, ITGA2 and MET signaling (2014) (174)
- GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer (2016) (173)
- Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. (2010) (172)
- DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. (2002) (165)
- The histone deacetylase SIRT2 stabilizes Myc oncoproteins (2012) (162)
- Expression of HOXB2, a Retinoic Acid Signaling Target in Pancreatic Cancer and Pancreatic Intraepithelial Neoplasia (2005) (161)
- Hypermutation In Pancreatic Cancer. (2017) (160)
- Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. (2001) (154)
- SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability (2011) (145)
- CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype (2018) (144)
- Differential requirement for ptf1a in endocrine and exocrine lineages of developing zebrafish pancreas. (2004) (140)
- Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. (2018) (135)
- Stabilization of beta-catenin induces pancreas tumor formation. (2008) (135)
- Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. (2013) (134)
- Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development (2017) (128)
- CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan (2019) (126)
- Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma (2016) (116)
- APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (2019) (115)
- Targeting mTOR dependency in pancreatic cancer (2014) (113)
- A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (113)
- Synoptic reporting improves histopathological assessment of pancreatic resection specimens (2009) (108)
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer (2013) (105)
- An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer (2017) (100)
- In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. (2008) (98)
- Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations (2010) (97)
- Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. (2016) (96)
- qpure: A Tool to Estimate Tumor Cellularity from Genome-Wide Single-Nucleotide Polymorphism Profiles (2012) (95)
- Pancreatic Intraepithelial Neoplasia in Association With Intraductal Papillary Mucinous Neoplasms of the Pancreas: Implications for Disease Progression and Recurrence (2004) (94)
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer (2017) (93)
- Chemotherapy and radiotherapy for advanced pancreatic cancer. (2018) (90)
- Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin. (2013) (87)
- Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer (2016) (84)
- Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects (2010) (82)
- Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. (2009) (81)
- Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. (2006) (80)
- Defining the molecular pathology of pancreatic body and tail adenocarcinoma (2018) (78)
- PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance (2016) (76)
- Consensus on precision medicine for metastatic cancers: a report from the MAP conference. (2016) (75)
- International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. (2016) (74)
- Precursor lesions in pancreatic cancer: morphological and molecular pathology (2011) (71)
- Repression of the Type I Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal Adenocarcinoma. (2020) (71)
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma (2021) (68)
- Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma (2003) (68)
- OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors (2017) (67)
- Factors influencing intention to undergo whole genome screening in future healthcare: a single-blind parallel-group randomised trial. (2012) (67)
- SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer (2017) (66)
- Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. (2020) (64)
- SOX9 regulates ERBB signalling in pancreatic cancer development (2014) (63)
- HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer (2020) (60)
- Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression Are Early Events in Prostate Cancer Development and Are Associated with Poor Prognosis (2006) (59)
- Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. (2013) (59)
- Somatic Point Mutation Calling in Low Cellularity Tumors (2013) (59)
- Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas (2011) (58)
- βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer (2014) (57)
- Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer (2019) (57)
- Long term nutritional status and quality of life following major upper gastrointestinal surgery - a cross-sectional study. (2011) (56)
- Clinical and pathologic features of familial pancreatic cancer (2014) (55)
- The deubiquitinase USP 9 X suppresses pancreatic ductal adenocarcinoma (2012) (53)
- DNA Polymerase Epsilon Deficiency Causes IMAGe Syndrome with Variable Immunodeficiency (2018) (53)
- The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy (2019) (53)
- Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction (2011) (53)
- Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. (2005) (51)
- Skills Acquired on Virtual Reality Laparoscopic Simulators Transfer into the Operating Room in a Blinded, Randomised, Controlled Trial (2007) (51)
- Pancreatic cancer genomics. (2014) (51)
- Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma (2017) (51)
- Mitochondrial mutations and metabolic adaptation in pancreatic cancer (2017) (50)
- BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer (2013) (49)
- BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer (2017) (49)
- Understanding pancreatic cancer genomes (2013) (42)
- Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. (2015) (42)
- Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities (2015) (42)
- Sex differences in oncogenic mutational processes (2019) (41)
- Mining the genomes of exceptional responders (2014) (41)
- The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling (2015) (41)
- ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling (2018) (40)
- Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review (2018) (39)
- Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis (2021) (38)
- Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. (2014) (37)
- Somatic variation and cancer: therapies lost in the mix (2011) (37)
- RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation. (2016) (37)
- Exome-Wide Association Study of Pancreatic Cancer Risk. (2017) (37)
- Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc (2014) (36)
- Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. (2020) (35)
- Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem? (2008) (35)
- Subtyping Pancreatic Cancer. (2015) (34)
- A Novel Approach to High Definition, High-Contrast Video Capture in Abdominal Surgery (2007) (33)
- Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma (2014) (31)
- The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome (2008) (31)
- Pancreas-Specific Sirt1-Deficiency in Mice Compromises Beta-Cell Function without Development of Hyperglycemia (2015) (31)
- Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 (2014) (30)
- Pancreatitis following human papillomavirus vaccination (2008) (29)
- New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. (2015) (29)
- Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling* (2016) (29)
- Cyclin E Expression and Outcome in Pancreatic Ductal Adenocarcinoma (2006) (29)
- Real Time Intraoperative Confocal Laser Microscopy-Guided Surgery (2009) (28)
- Lost in translation: returning germline genetic results in genome-scale cancer research (2017) (28)
- The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma (2017) (27)
- Defining research priorities for pancreatic cancer in Australia: results of a consensus development process (2010) (27)
- Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts (2017) (26)
- Surgical Therapy for Gastrointestinal Stromal Tumours of the Upper Gastrointestinal Tract (2009) (24)
- Signatures of mutational processes in human cancer this access benefits you. Your matters (2013) (23)
- Overexpression of p 21 WAF 1 / CIP 1 is an Early Event in the Development of Pancreatic Intraepithelial Neoplasia 1 (2001) (22)
- Personalising pancreas cancer treatment: When tissue is the issue. (2014) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Prolactin promotes fibrosis and pancreatic cancer progression. (2019) (22)
- Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions (2016) (22)
- Molecular Subtyping and Precision Medicine for Pancreatic Cancer (2021) (21)
- Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. (2019) (21)
- Returning individual research results for genome sequences of pancreatic cancer (2014) (21)
- DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association (2021) (20)
- Tumor mutational landscape is a record of the pre-malignant state (2019) (20)
- Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status (2010) (19)
- RON is not a prognostic marker for resectable pancreatic cancer (2012) (18)
- Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. (2019) (18)
- Low meprin α expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries (2006) (18)
- Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma (2020) (17)
- A histological survey of green fluorescent protein expression in ‘green’ mice: implications for stem cell research (2007) (17)
- Plexiform angiomyxoid myofibroblastic tumour of the stomach: a case report. (2010) (17)
- Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. (2021) (17)
- Role of endoscopic ultrasound in pancreatic cancer (2009) (17)
- Difficult to control asthma in children (2007) (17)
- PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. (2020) (16)
- The Challenges of Precision Oncology Drug Development and Implementation (2015) (16)
- Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity (2013) (16)
- Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status (2021) (16)
- Retinoid Signaling in Pancreatic Cancer, Injury and Regeneration (2011) (16)
- Abdominal shotgun wound with pellet embolization leading to bilateral lower limb amputation: case report and review of the literature of missile emboli over the past 10 years. (2009) (15)
- Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence (2021) (14)
- The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. (2015) (14)
- LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival (2021) (13)
- Erratum: Differential requirement for ptf1a in endocrine and exocrine lineages of developing zebrafish pancreas (Developmental Biology (2004) 270 (474-486) DOI: 10.1016/j.ydbio.2004.02.023) (2004) (13)
- The road to precision oncology (2017) (13)
- Corrigendum: Signatures of mutational processes in human cancer (2013) (13)
- Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes (2011) (13)
- Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. (2020) (13)
- APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC). (2016) (13)
- Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (12)
- FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs (2021) (11)
- MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity (2016) (11)
- Giant inguinal hernia containing right colon repaired using the prolene hernia system (2009) (11)
- APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA). (2014) (10)
- LMO4 expression in squamous cell carcinoma of the anterior tongue (2011) (10)
- Precision Oncology in Surgery (2018) (9)
- Messina: A Novel Analysis Tool to Identify Biologically Relevant Molecules in Disease (2009) (8)
- Defining the clinical genomic landscape for real-world precision oncology (2020) (8)
- Taking optical biopsies with confocal endomicroscopy (2009) (7)
- Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward (2021) (7)
- EXPRESSION OF S100A2 CALCIUM-BINDING PROTEIN PREDICTS RESPONSE TO PANCREATECTOMY FOR PANCREATIC CANCER (2008) (7)
- Pancreatic anomaly with multiple endocrine neoplasia type 1: a case of pancreas divisum and hemosuccus pancreaticus (santorinirrhage). (2008) (6)
- Can we move towards personalised pancreatic cancer therapy? (2014) (6)
- Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells (2021) (6)
- Differential requirement for ptf1a in endocrine and exocrine lineages of developing zebrafish pancreas. (2004) (6)
- Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours (2017) (6)
- Cancer Genetics and Implications for Clinical Management. (2015) (6)
- Individualizing therapy for pancreatic cancer (2008) (6)
- BRCA 2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer (2017) (5)
- PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development. (2019) (5)
- ICGC-ARGO precision medicine: familial matters in pancreatic cancer. (2022) (5)
- PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) – Part of Precision-Panc. (2018) (5)
- PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development. (2019) (5)
- Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage (2021) (5)
- Sirtuin-1 regulates acinar to ductal metaplasia and supports cancer cell viability in pancreatic cancer (2013) (5)
- Summary Notch inhibits Ptf 1 function and acinar cell differentiation in developing mouse and zebrafish pancreas (5)
- An unbiased high‐throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer (2020) (4)
- P-185Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT (2015) (4)
- S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704. (2011) (4)
- Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care (2022) (4)
- Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. (2019) (3)
- Novel cancer drivers: mining the kinome (2013) (3)
- Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation (2015) (3)
- Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses (2019) (3)
- The road ahead: less travelled and more arduous than initially envisioned (2011) (3)
- Biomarker assessment from EUS-guided biopsy to predict outcomes and treatment in pancreatic cancer. (2014) (3)
- Tumor and Stem Cell Biology Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial a 5 Integrin (2013) (3)
- 10. Precision Oncology in Surgery: Patient Selection Biomarkers for Operable Pancreatic Cancer (2018) (3)
- Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. (2019) (3)
- S100A4 as a biomarker of resistance to gemcitabine: A secondary analysis of RTOG 9704. (2012) (3)
- The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer (2021) (3)
- A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. (2014) (3)
- An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer (2019) (3)
- Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial. (2020) (2)
- Sa1369 Biomarker Assessment From EUS Guided Biopsy Predicts Survival Outcomes and Surgical Treatment in Pancreatic Carcinoma (2014) (2)
- ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. (2022) (2)
- Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer (2022) (2)
- Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. (2015) (2)
- FAK regulates IL-33 expression via chromatin accessibility and c-Jun (2020) (2)
- Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022) (2)
- Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials. (2013) (2)
- Defining DNA damage repair deficiency and replication stress in pancreatic cancer. (2019) (2)
- Role of endoscopic ultrasound in the management of pancreatic lesions (2008) (2)
- ROR1 and ROR2 expression in pancreatic cancer (2021) (2)
- Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
- Corrigendum: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma (2013) (2)
- Clinical utility of molecular profiling using EUS-guided Biopsies in Pancreatic cancer: The PRECISION-Panc experience (2018) (2)
- Pancreatic cancer: Challenges for therapeutic development (2014) (2)
- Diagnosis and Management of Hereditary Pancreatic Cancer. (2016) (2)
- Clinical utilization of targetable molecular results in pancreatic cancer: Longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. (2017) (1)
- DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association (2021) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- RON is not a prognostic marker for resectable pancreatic cancer (2012) (1)
- Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (1)
- P258 ASTERIX: Adaptive stratification of COVID19 to facilitate endotype-directed intervention studies (2021) (1)
- Molecular Subtyping of Pancreatic Cancer (2021) (1)
- The impact of on-site cytopathology on the clinical evaluation and management of patients who undergo eus-guided fine needle aspiration for suspected pancreatic cancer (2009) (1)
- Development of a biological resource for genomic characterisation of pancreatic cancer (2009) (1)
- Perspectives of International Association of Pancreatology (IAP)/European Pancreas Club (EPC) consensus review of guidelines for the future studies on clinical management of pancreatic cancer (2015) (1)
- Stratified medicine for pancreatic cancer (2014) (1)
- Targeting the Rho-ROCK pathway to treat pancreatic cancer: The use of unique preclinical models to ascertain the effects on cancer growth and metastasis. (2015) (1)
- Abstract A27: Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma (2016) (1)
- Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT) (2015) (1)
- nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT). (2015) (1)
- Abstract CT210: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial (2015) (1)
- Feasibility and clinical utility of EUS guided biopsy of pancreatic cancer for next-generation genomic sequencing. (2017) (1)
- Abstract A64: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. (2012) (1)
- 10. CLINICOPATHOLOGICAL FEATURES OF HER2 AMPLIFIED PANCREATIC CANCER (2014) (1)
- Precision-Panc Master Protocol: Personalizing treatment for pancreatic cancer ISRCTN14879538—Part of Precision-Panc United Kingdom. (2019) (1)
- Use of the novel biomarker (HOXB2) to predict response to pancreatectomy for pancreatic cancer (2007) (1)
- 314 The Novel Biomarker (HOXB2) Predicts Response to Pancreatectomy for Pancreatic Cancer (2008) (1)
- Cancer Cell Viability in Pancreatic Cancer Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports (2013) (1)
- COVID-19 provides an opportunity to transform cancer research (2021) (1)
- Abstract 3005: International Cancer Genome Consortium (2018) (1)
- S100A2 (S100 calcium binding protein A2) (2012) (1)
- Abstract LB-395: Hepatocyte growth factor: a potential therapeutic target in pancreatic cancer (2011) (1)
- Lost in translation: returning germline genetic results in genome-scale cancer research (2017) (1)
- Abstract SY10-02: Pan-cancer study of recurrent and heterogeneous RNA aberrations and association with whole-genome variants (2017) (1)
- CXCR 2 Inhibition Profoun dly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma Graphical Abstract Highlights (2016) (1)
- Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. (2023) (1)
- Pharmacological targeting of TFIIH suppresses KRAS mutant pancreatic ductal adenocarcinoma and synergizes with TRAIL. (2022) (1)
- Role of chemoradiation in locally advanced pancreatic cancer: A systematic review and meta-analysis. (2015) (1)
- PANCREATIC STELLATE CELLS STIMULATE ANGIOGENESIS IN PANCREATIC CANCER AND ACCOMPANY PANCREATIC CANCER CELLS TO DISTANT METASTATIC SITES (2008) (1)
- Abstract A02: Assessment of germline cancer predisposition genes in 392 unselected pancreatic cancer patients (2016) (1)
- Genome sequencing with gene panel-based analysis for rare inherited conditions in a publicly funded healthcare system: implications for future testing (2022) (1)
- Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy (2020) (1)
- Clinical and molecular characterization of HER2amplified-pancreatic cancer (2013) (1)
- Defining DDR defectiveness in pancreatic cancer. (2017) (1)
- Pathology as the cornerstone of human tissue banking: experiences in the post-genomics era (2011) (1)
- Sca1+/CD31−/PDGFRa+ Cardiac Stem Cells are from an Epicardial/Mesodermal but not Neural-crest, Cardiomyocyte or Bone-marrow Origin (2009) (1)
- Mitochondrial mutations and metabolic adaptation in pancreatic cancer (2017) (1)
- Recurrent noncoding regulatory mutations in pancreatic ductal 1 adenocarcinoma 2 3 4 5 6 7 (2017) (0)
- Abstract 3485: Cardiac Stem Cells Defined by Colony Forming Unit Assays Are From an Epicardial/Mesodermal but Not Neural-Crest, Cardiomyocyte or Bone-Marrow Origin (2009) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- 3517 POSTER The novel biomarker (HOXB2) predicts response to pancreatectomy for pancreatic cancer (2007) (0)
- Abstract 5071: The genomic landscape of pancreatic cancer: from discovery to patient care (2012) (0)
- 706 Altered Expression of Sirtuin-1 or Its Inhibitor Deleted in Breast Cancer-1 Affects Premalignant Changes in Mouse Exocrine Tissue and Growth of Human Pancreatic Ductal Adenocarcinoma Cells (2012) (0)
- Abstract C085: Spatial arrangements of immune cells of the pancreatic ductal adenocarcinoma tumor microenvironment correlated with outcomes in the phase 3 APACT trial (2022) (0)
- LOSS OF CRBP1 EXPRESSION, A KEY COMPONENT OF RETINOIC ACID SIGNALLING, IS A COMMON AND EARLY EVENT IN PANCREATIC CANCER (2007) (0)
- Abstract IA3: Genomic analysis reveals roles for chromatin modification and axon guidance in pancreatic cancer. (2012) (0)
- Targeted therapies in the treatment of advanced pancreatic adenocarcinoma (PC): A systematic review and meta-analysis of randomized trials. (2014) (0)
- Abstract PR06: The ampullary adenocarcinoma, its molecular characterization and differentiation from the pancreatic ductal adenocarcinoma, duodenal adenocarcinoma, and cholangiocarcinoma (2015) (0)
- Molecular Oncology: Molecular profiling and therapeutic decision-making: the promise of personalized medicine (2013) (0)
- Abstract C051: Ceramide signaling regulates PDA aggression through exosome reprogramming of the stroma (2022) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. (2022) (0)
- 1079: Neuropeptide Y Expression is increased in the Progression from Benign to Malignant Prostate Epithelium and Predicts Outcome after Radical Prostatectomy (2004) (0)
- 54. Sclerosing angiomatoid nodular transformation of the spleen: a report of two cases (2011) (0)
- PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. (2012) (0)
- Endocrine cells of transitional mucosa adjacent to colonic adenocarcinoma. (1995) (0)
- 811 Development of a Fast in Vitro Assay to Screen New Gene Aberrations Identified Through Genomic Analysis of Pancreatic Tumours as Possible Drivers of Early Carcinogenesis (2012) (0)
- Transcriptomic dissection of Intraepithelial Papillary Mucinous Neoplasms progression by spatial technologies identified novel markers of pancreatic carcinogenesis (2022) (0)
- S1820 Heat Shock Proteins Are Induced During Pancreatic Stellate Cell Activation in Pancreatic Cancer (2009) (0)
- FORTHCOMING ARTICLES NOVEMBER 2009 (2009) (0)
- Reply to G.F. Arroyo. (2013) (0)
- Abstract C20: Smpd3 augments chemotherapy and thwarts PDA progression (2019) (0)
- Effect of Rho/ROCK pathway inhibition on metastasis-free and overall survival in biomarker selected, orthotopic, patient-derived models of pancreatic cancer. (2017) (0)
- CDK7 inhibition augments the response against multidrug chemotherapy in pancreatic cancer (2022) (0)
- The integrin αvβ6 is a promising therapeutic target for treating PDAC (2016) (0)
- Abstract 2031: High plex proteomic prognostic marker discovery for patients with pancreatic adenocarcinoma using digital spatial profiling (2022) (0)
- 91 Proffered Paper: Testing Individualised Treatment Strategies in Preclinical Models of Pancreatic Cancer (2012) (0)
- Abstract A100: ROBO2 is a stroma suppressor gene in the pancreas through regulation of TGF-β (2019) (0)
- 648 Adjuvant Chemotherapy Is More Beneficial in Elderly Patients with Resected Pancreatic Cancer (2008) (0)
- Bridging the implementation gap: delivering complex genomic analysis for routine cancer care. (2022) (0)
- PrecisionPanc, Personalised treament for pancreatic cancer, Wellcome Trust (2018) (0)
- 9. CYCLIN-DEPENDENT KINASE INHIBITOR AS A POTENTIAL NOVEL THERAPEUTIC AGENT FOR PANCREATIC CANCER (2014) (0)
- Clinical Practice (2010) (0)
- Abstract 1762: Keratin 17 identifies prognostic subtypes of pancreatic ductal adenocarcinoma (2017) (0)
- ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer. (2023) (0)
- FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs (2021) (0)
- Abstract 5138: Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 (2014) (0)
- CLINICOPATHOLOGICAL FEATURES OF PANCREATIC SOLID PSEUDOPAPILLARY TUMORS (2008) (0)
- ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. (2022) (0)
- Basic Science Luminal (2011) (0)
- Pancreatic Cancer: Methods and Protocols (2005) (0)
- Loss of Special at Rich Binding Protein 1 (SATB1) Correlates With Poor Survival in Patients With Colorectal Cancer (2011) (0)
- Returning individual research results for genome sequences of pancreatic cancer (2014) (0)
- Abstract PR10: CXCR2 Inhibition Suppresses Metastasis and Improves the Response to Immunotherapy in Pancreatic Cancer (2016) (0)
- Companion Diagnostics and Biomarkers BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer (2013) (0)
- PRECISION-PANC (2020) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Management of Nutritional Issues After Major Pancreatic Resections (2009) (0)
- Novel cancer drivers: mining the kinome (2013) (0)
- Abstract C39: A novel rewired pathway of nucleotide metabolism drives chemoresistance in pancreatic cancer (2019) (0)
- Abstract A75: The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer. (2013) (0)
- Altered Slit-Robo signalling activates TGF-beta signalling and stroma remodelling in the pancreas. (2017) (0)
- AB001. S001. Defining DDR deficiency and replication stress in pancreatic cancer (2018) (0)
- Cancer Therapy : Preclinical Gemcitabine and CHK 1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma (2014) (0)
- Expression of the axon guidance protein Robo1 in pancreatic ductal adenocarcinoma from smokers compared to nonsmokers. (2015) (0)
- Referee acknowledgement for 2019 (2020) (0)
- Nones, K. et al. (2014) Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT- (2014) (0)
- From functional genomics to precision medicine: The therapeutic potential of targeting ROCK signaling in pancreatic cancer. (2013) (0)
- Abstract B53: The integrin αvβ6 is a promising therapeutic target for treating PDAC (2016) (0)
- Abstract A73: Altered expression of sirtuin 1 and Deleted in Breast Cancer 1 and its functional impact on pancreatic carcinogenesis. (2012) (0)
- REFEREES (2007) (0)
- Precision medicine for pancreatic cancer in national health care system: The initial Precision-Panc experience (2020) (0)
- Recognition of USA 300 isolates of community-acquired methicillin-resistant Staphylococcus aureus in Australia 179 (2006) (0)
- Tobogganing Injuries in Australia (1993) (0)
- Treatment of pancreatic cancer in 2022 (2023) (0)
- The association between KRAS mutational status, clinicopathological factors including the preoperative systemic inflammatory response and outcomes in TNM stage I-III colon cancer. (2023) (0)
- A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. (2014) (0)
- Molecular Diagnostics: Translation from Discovery to Clinical Practice (2016) (0)
- Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin (2019) (0)
- Abstract PO-008: Multi-omic Profiling of primary pancreatic adenocarcinomas obtained from the APACT adjuvant trial of nab-paclitaxel + gemcitabine vs gemcitabine (2020) (0)
- Abstract 3027: SIRT1 promotes N-Myc oncogenesis stabilizing N-Myc protein (2011) (0)
- W1685 Intra-Operative Application of the Hand-Held Confocal Microscope - a Pilot Study (2008) (0)
- Abstract IA-12: Precision oncology for pancreatic cancer (2020) (0)
- Abstract LB-73: SOX9 regulates EGFR/ERBB signaling in pancreatic cancer (2014) (0)
- Acknowledgement to Reviewers (2012) (0)
- APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC): 232 (2014) (0)
- Spatially Resolved Transcriptomics Deconvolutes Histological Prognostic Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases (2022) (0)
- Pathology and Molecular Biology of Intraductal Papillary Mucinous Neoplasms (2008) (0)
- Frameshift mutations of ATBF1, WNT9A, CYLD and PARK2 in gastric and colorectal carcinomas with high microsatellite instability (2010) (0)
- Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin (2022) (0)
- Abstract 4866: The atypical kinase SgK223 is a novel mediator of cell invasion in pancreatic cancer (2012) (0)
- 04 WHOLE GENOME SEQUENCING INFORMS THERAPEUTIC SELECTION FOR PANCREATIC CANCER (2014) (0)
- Referee Acknowledgement for 2016 (2017) (0)
- TRANSDIFFERENTIATION OF BONE MARROW DERIVED STEM CELLS INTO MATURE PANCREATIC ACINAR CELLS (2008) (0)
- Web-based tools for integrative analysis of pancreatic cancer data (2016) (0)
- Returning Genetic Research Results to Individuals: The International Cancer Genome Consortium Initiative Experience (2011) (0)
- S2024 Utilization and Benefit of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer (2009) (0)
- CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer (2022) (0)
- Abstract 815: Precision medicine for pancreatic cancer in national health care system: The initial Precision Panc experience (2020) (0)
- Abstract 4869: Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects (2010) (0)
- Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. (2022) (0)
- 108 The Deubiquitinase USP9X Suppresses Pancreatic Ductal Adenocarcinoma (2012) (0)
- CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer (2022) (0)
- Abdominal pain: is it the pancreas? (2007) (0)
- Retinoids, in combination with Histone Deacetylase (HDAC) inhibitors, as a potential therapy for pancreatic cancer (2008) (0)
- Novel use of patient activated pump for ambulant regional chemotherapy (1996) (0)
- Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases (2023) (0)
- Cancer genomes and clinical care (2011) (0)
- The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling (2015) (0)
- Abstract PO-023: Targeting a novel rewired pathway of nucleotide metabolism that drives chemoresistance in the most lethal molecular subtype of pancreatic cancer (2020) (0)
- Abstract 1156: A molecular pre-operative prognostic nomogram for resectable pancreatic cancer. (2012) (0)
- ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling (2018) (0)
- Methylation of the Mcc Gene Predicts a More Aggressive Colorectal Cancer Phenotype (2011) (0)
- Abstract 1176: Leveraging the GENIE dataset to distinguish somatic cancer drivers from passenger events in routine oncology practice (2022) (0)
- Abstract 985: The EurOPDX EDIReX project: Towards a European research infrastructure on patient-derived cancer models (2018) (0)
- Pancreas and Biliary Tree (2015) (0)
- Meeting the Need for a Discussion of Unmet Medical Need (2022) (0)
- Abstract B76: Translating keratin 17 status to stratify clinically relevant pancreatic cancer heterogeneity and survival (2016) (0)
- 746TiPAPACT: A PHASE III TRIAL OF NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR RESECTED PANCREATIC CANCER (PC). (2014) (0)
- The utility of the AJCC 8th staging criteria in the era of neoadjuvant therapy and molecular subtyping for pancreatic cancer (2020) (0)
This paper list is powered by the following services:
Other Resources About Andrew Biankin
What Schools Are Affiliated With Andrew Biankin?
Andrew Biankin is affiliated with the following schools:
